Liposome-based immunotherapy against autoimmune diseases: Therapeutic effect on multiple sclerosis

Irma Pujol-Autonell, Maria Jose Mansilla, Silvia Rodriguez-Fernandez, Mary Cano-Sarabia, Juan Navarro-Barriuso, Rosa Maria Ampudia, Aleix Rius, Sonia Garcia-Jimeno, David Perna-Barrull, Eva Martinez Caceres, Daniel Maspoch, Marta Vives-Pi

    Research output: Contribution to journalArticleResearchpeer-review

    38 Citations (Scopus)


    © 2017 Future Medicine Ltd. Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. Materials & methods: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. Results: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. Conclusion: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.
    Original languageEnglish
    Pages (from-to)1231-1242
    Issue number11
    Publication statusPublished - 1 Jun 2017


    • Autoimmunity
    • Experimental autoimmune encephalomyelitis
    • Immunotherapy
    • Liposomes
    • Multiple sclerosis


    Dive into the research topics of 'Liposome-based immunotherapy against autoimmune diseases: Therapeutic effect on multiple sclerosis'. Together they form a unique fingerprint.

    Cite this